GEN Exclusives

More »

GEN News Highlights

More »
Oct 30, 2012

TPP, Sprint Partner on Anticancer Choline Kinase Inhibitors

  • TPP Global Development and Sweden’s Sprint Biosciences inked a collaboration focused on the development of small molecule choline kinase inhibitors for the treatment of cancer. U.K-based TPP is a drug development firm focused on acquiring preclinical drug programs from industry, universities, and research institutes, and continuing development to the point at which the drug candidates can be licensed out to the pharma or bioindustries, or spun out into a newly established development entity.

    TPP’s current therapeutic areas include neuroscience, immunology, inflammation, and cancer, and it currently has six drug discovery programs in development. 

    Drug discovery firm Sprint is exploiting its fragment-based drug discovery platform Gene2Lead™ to identify and take into preclinical development drugs that target cancer metabolism and autophagy. The firm’s choline kinase inhibitor program is built on evidence indicating that increased choline kinase activity is required by cancer cells to generate the cell membrane phospholipid component phosphatidylcholine, and that the enzyme’s activity is involved in cell transformation. Sprint is running a fragment-based drug discovery program to identify small molecules that target choline kinase α. 

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »